Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has corrected its Audit Report Submission disclosure to rectify the receipt date (from 2023 to 2024), confirming an ‘Unqualified’ audit opinion from its external auditor for FY2023 consolidated revenue of KRW 3.69T and operating profit of KRW 1.11T.
📊 [Key Disclosure Details & Financial Figures]
- Reason for Correction: Correction of audit report receipt date
- Corrected Item: Audit report receipt date (Pre-correction: 2023-02-28 → Post-correction: 2024-02-28)
- External Auditor: Samil PricewaterhouseCoopers
- Audit Opinion & Major Items (Both Consolidated and Separate):
- Audit Opinion: Unqualified
- Issues Regarding Going Concern Uncertainty: Not Applicable
- Adverse Opinion on Internal Accounting Control System: Not Applicable
- Embezzlement or Breach of Fiduciary Duty Mentioned in Audit Report: No
- FY2023 Consolidated Financial & Earnings Figures:
- Total Assets: KRW 16,046,197,209,196
- Total Liabilities: KRW 6,215,704,796,851
- Total Equity: KRW 9,830,492,412,345 (Capital Stock: KRW 177,935,000,000)
- Revenue: KRW 3,694,588,767,068 (Prior FY: KRW 3,001,295,197,683)
- Operating Profit: KRW 1,113,680,009,715 (Prior FY: KRW 983,627,394,377)
- Profit Before Income Tax Expenses: KRW 1,119,986,931,201
- Net Profit: KRW 857,691,298,384 (Same as Net Profit Attributable to Owners of Parent)
- Number of Consolidated Subsidiaries: 14 (Major Subsidiaries: 1)
- FY2023 Separate Financial & Earnings Figures:
- Total Assets: KRW 11,831,260,604,556
- Total Liabilities: KRW 3,592,626,821,824
- Total Equity: KRW 8,238,633,782,732 (Capital Stock: KRW 177,935,000,000)
- Revenue: KRW 2,938,755,680,729 (Prior FY: KRW 2,437,286,111,838)
- Operating Profit: KRW 1,204,187,993,041 (Prior FY: KRW 968,050,593,669)
- Profit Before Income Tax Expenses: KRW 1,224,183,412,500
- Net Profit: KRW 945,920,325,918
- Other Remarks: Financial statements are subject to potential changes during the approval process at the Annual General Meeting of Shareholders.
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Final Shareholder Approval and Financial Statement Confirmation
This correction disclosure rectifies a clerical error regarding the audit report receipt date while confirming an ‘Unqualified’ audit opinion issued by Samil PricewaterhouseCoopers. Tracking whether the audited financial figures pass through the Annual General Meeting without modifications is essential to verify the finality and reliability of the reported financial data. Investors can confirm the finalized figures through the subsequent Results of Annual General Meeting disclosure and the Annual Report.
📢 Disclaimer and Source Notice
Source: This content was structured and newly generated based on official submission data from the Financial Supervisory Service DART system.
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial liabilities rest entirely with the individual investor.
Contact: For regulatory compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
